Business Context and Reporting Period
Company: Alphatec Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 27, 2006
Event: Entry into Material Definitive Agreements for the acquisition of a controlling interest in Scient'x, S.A., a French medical device manufacturer.
Key Financial Metrics and Transaction Details
This filing details a strategic acquisition rather than periodic financial performance. Key transaction metrics include:
- Total Acquisition Target: 74.1% of the outstanding capital stock of Scient'x, S.A.
- Transaction 1 (Carli Agreement):
- Target: 2.15 million shares of Ideal Medical Products (61.3% ownership).
- Total Consideration: Approximately $70.2 million.
- Price Per Share: Approximately $32.69.
- Payment Structure: 15% cash, 85% Alphatec common stock.
- Transaction 2 (Luxco Agreement):
- Target: 3.95 million shares of Scient'x (33.1% ownership) via HealthPoint (Luxembourg) I.
- Total Consideration: Approximately $56.5 million.
- Payment Structure: 100% Alphatec common stock.
- Stock Issuance Pricing: Based on weighted-average trading price between September 27, 2006, and 20 days prior to the shareholder vote, capped at $9.50 and floored at $5.00.
Note: The filing does not provide Alphatec's current revenue, profit, cash flow, or debt levels.
Material Changes and Future Actions
Upon closing, Alphatec will directly and indirectly own 61.3% of Ideal Medical and 74.1% of Scient'x. Following the closing, the Company plans to initiate a tender offer to purchase all remaining shares of Ideal Medical not already held. The tender offer terms will be substantially equivalent to the Carli Agreement but will include an option for shareholders to receive consideration entirely in cash.
Conditions, Risks, and Contingencies
The closing of these transactions is subject to several material conditions:
- Approval by Alphatec's shareholders.
- Obtaining necessary financing to fund the transaction.
- Approval from all applicable anti-trust agencies.
Mr. Carli will receive registration rights related to the resale of the common stock he receives.
Investor Verification Checklist
- Verify the final number of shares to be issued based on the weighted-average trading price formula.
- Confirm the status of required financing and anti-trust approvals.
- Review the full text of the Carli Agreement (Exhibit 10.1) and Luxco Agreement (Exhibit 10.2) for detailed covenants.
- Monitor the upcoming shareholder meeting vote on the transaction.
- Assess the dilution impact of the stock issuance on existing shareholders.